Origami Therapeutics, Inc.

Winter 2022Active

Oral drugs to halt neurodegeneration

Save

Origami Therapeutics, Inc.

Winter 2022Active

Oral drugs to halt neurodegeneration

Save

Company details

Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified small molecules that reduce the toxic mutated protein, suppress mutant protein-induced toxicities in human disease neurons and get into the brain. We anticipate that this approach will be broadly applicable to traditionally “undruggable” targets in other neurological diseases.

Location

San Diego, CA, USA

Founded

Unknown

Upgrade to Pro, then request the Origami Therapeutics, Inc. teardown.

This company does not have a completed analysis yet. Choose a Pro plan first, then use one of your 5 monthly research requests to have our agent investigate Origami Therapeutics, Inc.. The full teardown, rebuild plan, and technical specs unlock when it lands.

Use Pro to request the first Origami Therapeutics, Inc. teardown and keep the finished report in your account.
Read every completed teardown and rebuild plan already in the database.
Unlock implementation-ready technical specs and 5 fresh research requests each month.

Choose your Pro plan

$20/ month

Find one worth rebuilding, get the teardown, open the implementation-ready specs, and use fresh report requests when you want deeper research.

See Pro plans

Full teardown library

Specs for every company

5 fresh requests / month

CLI for agent imports